Abstract: A device and method for dispensing a friction-coefficient-optimizing mixture of at least one lubricant and at least one grit into the gap between a rail wheel of a rail vehicle and a rail. The device includes a reservoir for the lubricant, a reservoir for the grit, a metering unit for metering the lubricant, a metering unit for metering the grit, a delivery apparatus for delivering the lubricant, a delivery apparatus for delivering the grit, and a common dispensing nozzle. The apparatus for delivering the lubricant and the apparatus for delivering the grit are separate from each other and end in the common dispensing nozzle, the friction-coefficient-optimizing mixture therefore not being formed until the dispensing, and an additional compressed air line is provided, which ends in the common dispensing nozzle.

Abstract: A device and method for dispensing a friction-coefficient-optimizing mixture of at least one lubricant and at least one grit into the gap between a rail wheel of a rail vehicle and a rail. The device includes a reservoir for the lubricant, a reservoir for the grit, a metering unit for metering the lubricant, a metering unit for metering the grit, a delivery apparatus for delivering the lubricant, a delivery apparatus for delivering the grit, and a common dispensing nozzle. The apparatus for delivering the lubricant and the apparatus for delivering the grit are separate from each other and end in the common dispensing nozzle, the friction-coefficient-optimizing mixture therefore not being formed until the dispensing, and an additional compressed air line is provided, which ends in the common dispensing nozzle.

Abstract: The present invention relates to compositions comprising a construct comprising the A?1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.

Abstract: The present invention relates to compositions comprising a construct comprising the A?1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.

Abstract: The present invention relates to compositions comprising a construct comprising the A?1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.

Abstract: The invention concerns the use of competitive AMPA receptor antagonists for the treatment or prevention of photosensitive epilepsy.

Abstract: The invention concerns the use of competitive AMPA receptor antagonists for the treatment or prevention of photosensitive epilepsy.

Abstract: The present invention relates to compositions comprising a construct comprising the A?1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. In one embodiment, the construct containing the A?1-6 peptide consists of a virus-like particle (VLP) of the RNA bacteriophage Q? chemically coupled to said A?1-6 peptide.

Abstract: A polynucleotide comprising an Skp 2 promoter sequence is provided. The promoter is useful in tumour and cancer therapy, in particular in therapies that are intended to selectively kill or reduce the growth, division or viability of tumour or cancer cells compared to surrounding, non-tumour or non-cancer cells. Also provided are methods for screening for inhibitors of Skp2 promoter activity.

Abstract: Methods are disclosed for fast and accurate readout of kidney toxicity before it occurs and before it is demonstrated by histopathology examination. Ultimately, this approach shall allow earlier compound selection. The twelve genes identified, namely Calbindin-D28k, KIM-1, OPN, EGF, Clusterin, VEGF, OAT-K1, Aldolase A, Aldolase B, Podocin, Alpha-2u and C4, were grouped and ultimately can be assessed in the form of a kit using PCR, a high throughput technology, in order to characterize and rank new compounds according to their anticipated general kidney toxicity. Also disclosed are methods for identifying agents useful in the treatment of kidney disease, methods for monitoring the efficacy of a treatment for kidney disease and kidney-specific vectors including the sequences of the disclosed genes, and a method for identifying a candidate gene associated with a biological process including kidney function.

Abstract: A polynucleotide comprising an Skp 2 promoter sequence is provided. The promoter is useful in tumour and cancer therapy, in particular in therapies that are intended to selectively kill or reduce the growth, division or viability of tumour or cancer cells compared to surrounding, non-tumour or non-cancer cells. Also provided are methods for screening for inhibitors of Skp2 promoter activity.